Merck & Co. (MRK) : Parthenon scooped up 950 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 26, 2016. The investment management firm now holds a total of 180,743 shares of Merck & Co. which is valued at $10,591,540.Merck & Co. makes up approximately 2.62% of Parthenon’s portfolio.
Other Hedge Funds, Including , Calamos Advisors reduced its stake in MRK by selling 350,687 shares or 21.31% in the most recent quarter. The Hedge Fund company now holds 1,295,052 shares of MRK which is valued at $75,890,047. Merck & Co. makes up approx 0.69% of Calamos Advisors’s portfolio.Concorde Asset Management reduced its stake in MRK by selling 173 shares or 2.61% in the most recent quarter. The Hedge Fund company now holds 6,448 shares of MRK which is valued at $379,271. Merck & Co. makes up approx 0.37% of Concorde Asset Management’s portfolio.Boston Common Asset Management reduced its stake in MRK by selling 4,455 shares or 2.72% in the most recent quarter. The Hedge Fund company now holds 159,415 shares of MRK which is valued at $9,372,008. Merck & Co. makes up approx 1.35% of Boston Common Asset Management’s portfolio.Acadian Asset Management boosted its stake in MRK in the latest quarter, The investment management firm added 2,624 additional shares and now holds a total of 22,425 shares of Merck & Co. which is valued at $1,318,366. Merck & Co. makes up approx 0.01% of Acadian Asset Management’s portfolio.Trust Department Mb Financial Bank N A reduced its stake in MRK by selling 434 shares or 10.39% in the most recent quarter. The Hedge Fund company now holds 3,742 shares of MRK which is valued at $220,853. Merck & Co. makes up approx 0.02% of Trust Department Mb Financial Bank N A’s portfolio.
Merck & Co. opened for trading at $59.01 and hit $59.2 on the upside on Friday, eventually ending the session at $58.66, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 84,91,237 shares. Company has a market cap of $162,372 M.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Investors should note that on Jul 26, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Sep 13, 2016 as the ex-dividend date and fixed the record date on Sep 15, 2016. The payable date has been fixed on Oct 7, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.